Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
Yue Yuan; Hongkai Yan; Qinhang WuShow moreShow less
1. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, ChinaShow moreShow less
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330
Hamid BelloutShow moreShow less
1. Northern Illinois University, DeKalb, USAShow moreShow less
Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models
Hiroshi Yuita; Sadanori Watanabe; Jun Tsukada; Yoshikazu Johmura; Sae Aratani; Hirokazu Ishikawa; Ryuichi Nakamura; Miki Yokoyama; Mari Hashimoto; Hideo Yukinaga; Huynh The Hung; Makoto Nakanishi; Keisuke FukuchiShow moreShow less
1. Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2. Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 3. Division of Cancer and Senescence Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 4. Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5. Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 6. Translational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 7. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8. Daiichi Sankyo Inc., Basking Ridge, USA; 9. Division of Cellular and Molecular Research, National Cancer Centre, Singapore, SingaporeShow moreShow less
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer
Fengting Yan; Marcia Cruz-Correa; Jennifer Specht; Edward Wenge Wang; Jinyu Lu; Hatem Soliman; Amy Jackson-Fisher; Szu-Yu Tang; Sibo Jiang; Christophe Le Corre; Meng Li; David SommerhalderShow moreShow less
1. Swedish Cancer Institute, Seattle, USA; 2. Pan American Center for Oncology Trials, San Juan, USA; 3. Fred Hutchinson Cancer Center, Seattle, USA; 4. City of Hope Comprehensive Cancer Center, Duarte, USA; 5. Montefiore Einstein Comprehensive Cancer Center, Bronx, USA; 6. Moffitt Cancer Center, Tampa, USA; 7. Pfizer, San Diego, USA; 8. Pfizer, South San Francisco, USA; 9. NEXT Oncology, San Antonio, USAShow moreShow less
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer
Jordi Rodon; Bert O’Neil; Christopher Lim; Natraj R. Ammakkanavar; Carlos Torrado; Kazuaki Matsuoka; Hiroshi Hirai; Akihiro Miura; Bailey Anderson; Leah Jin; Nanae Hangai; Amanda Long; Volker Wacheck; Lee RosenShow moreShow less
1. MD Anderson Cancer Center, Houston, USA; 2. Community Health Network, Indianapolis, USA; 3. Division of Hematology-Oncology, UCLA, Los Angeles, USA; 4. Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; 5. Taiho Oncology, Inc., Princeton, USAShow moreShow less
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran; Christina Guo; Simon Pacey; Guillermo Villacampa; Ruth Matthews; Toby Prout; Joan Fernandes; Alison Turner; Mona Parmar; Ruth Riisnaes; Ana Ferreira; Suzanne Carreira; Claudia Bertan; Mateus Crespo; Ines Figueiredo; Wei Yuan; Denisa Bogdan; Florence Raynaud; Ruth Ruddle; Bianca Calì; Martino Maddalena; Arianna Calcinotto; Christina Yap; Adam Sharp; Andrea Alimonti; Johann De Bono; Alec PaschalisShow moreShow less
1. Institute of Cancer Research, London, UK; 2. The Royal Marsden NHS Foundation Trust, London, UK; 3. Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK; 4. Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 5. Institute of Oncology Research (IOR), Bellinzona, Switzerland; 6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland; 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8. Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland; 9. Department of Medicine, University of Padova, Padua, ItalyShow moreShow less
FAQ
How long does INVESTIGATIONAL NEW DRUGS take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for INVESTIGATIONAL NEW DRUGS. The fastest paper went from submission to acceptance in 25 days (Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials, received 2026-08-12, accepted 2026-09-06); the slowest took 160 days. The average is 71 days and the median is 66 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
